Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure
The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study